论文部分内容阅读
为观察血管紧张素转换酶抑制剂 (ACEI)苯那普利对改善糖尿病肾病 (DN)患者肾脏病变的疗效 ,选择 1998年 1月至 1999年 12月 5 4例 型糖尿病伴肾脏病变患者 ,随机分为 A、B两组 ,均坚持饮食控制和降糖治疗 ,停服 ACEI两周后 ,A组给予苯那普利 10 mg/d晨间口服 6个月 ,B组不服 ACEI。检测两组实验初及 6个月时空腹血糖 (FBG)、血尿素 (BU N)、血肌酐 (Scr)、糖化血红蛋白 (Hb A1c)、尿白蛋白排泄量 (UAE)、血清 型胶原 (C )和层粘蛋白(L N)并比较。结果表明 ,苯那普利治疗后 U AE、C 、L N均较治疗前以及未予治疗组明显降低 ,UAE减少与 C 、L N水平降低呈显著正相关关系。说明苯那普利对治疗 DN、延缓肾病进展及改善肾功能有较好疗效
To observe the curative effect of benazepril, an angiotensin converting enzyme inhibitor (ACEI), on nephropathy in patients with diabetic nephropathy (DN), 54 patients with type 4 diabetes mellitus and kidney disease from January 1998 to December 1999 were selected and randomized Divided into A, B two groups, both adhere to diet control and hypoglycemic therapy, stop taking ACEI two weeks later, group A was given benazepril 10 mg / d morning orally for 6 months, group B was not convinced ACEI. The levels of fasting blood glucose (FBG), blood urea nitrogen (BU N), serum creatinine (Scr), Hb A1c, urinary albumin excretion (UAE), serum C ) And laminin (LN) and compared. The results showed that after benazepril treatment UAE, C, L N were significantly lower than before treatment and no treatment group, UAE decreased and C, L N decreased significantly positively correlated. Description benazepril on the treatment of DN, delay the progression of nephropathy and improve renal function have a good effect